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ABSTRACT Extraintestinal pathogenic Escherichia coli (ExPEC) strains belonging to
multilocus sequence type 95 (ST95) are globally distributed and a common cause of
infections in humans and domestic fowl. ST95 isolates generally show a lower prevalence of acquired antimicrobial resistance than other pandemic ExPEC lineages. We
took a genomic approach to identify factors that may underlie reduced resistance.
We fully assembled genomes for four ST95 isolates representing the four major
ﬁmH-based lineages within ST95 and also analyzed draft-level genomes from another 82 ST95 isolates, largely from the western United States. The fully assembled
genomes of antibiotic-resistant isolates carried resistance genes exclusively on large
(⬎90-kb) IncFIB/IncFII plasmids. These replicons were common in the draft genomes
as well, particularly in antibiotic-resistant isolates, but we also observed multiple instances of a smaller (8.3-kb) ampicillin resistance plasmid that had been previously
identiﬁed in Salmonella enterica. Among ST95 isolates, pansusceptibility to antibiotics
was signiﬁcantly associated with the ﬁmH6 lineage and the presence of homologs of
the previously identiﬁed 114-kb IncFIB/IncFII plasmid pUTI89, both of which were
also associated with reduced carriage of other plasmids. Potential mechanistic explanations for lineage- and plasmid-speciﬁc effects on the prevalence of antibiotic resistance within the ST95 group are discussed.
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IMPORTANCE Antibiotic resistance in bacterial pathogens is a major public health
concern. This work was motivated by the observation that only a small proportion
of ST95 isolates, a major pandemic lineage of extraintestinal pathogenic E. coli, have
acquired antibiotic resistance, in contrast to many other pandemic lineages. Understanding bacterial genetic factors that may prevent acquisition of resistance could
contribute to the development of new biological, medical, or public health strategies to reduce antibiotic-resistant infections.
KEYWORDS Escherichia coli, ExPEC, ST95, antibiotic resistance, genomics

G

enetically diverse strains of the Gram-negative bacterium Escherichia coli are
capable of causing many human illnesses, including both gastrointestinal and
extraintestinal infections. This species is the most common cause of urinary tract
infections (UTIs) (1) and a leading cause of bloodstream infections (BSIs) (2). With few
exceptions, E. coli strains with an enhanced ability to cause extraintestinal infections—
referred to collectively as extraintestinal pathogenic E. coli (ExPEC)—are genetically
distinct from strains that cause gastrointestinal illness (3). Epidemiological observations
have shown that ExPEC strains are derived primarily from a small number of phylogenetic lineages, as deﬁned by multilocus sequence typing (MLST), including sequence
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types 131 (ST131), ST95, ST69, ST73, and ST393. These STs are responsible for nearly half
of all E. coli UTIs or BSIs in many regions of the world (4). Comparative genomic analysis
of ExPEC strains to date has not conclusively identiﬁed essential “pandemicity” genes
in these lineages (5), but there is considerable interest in understanding virulenceassociated genetic features of pandemic ExPEC lineages.
In several recent surveys of ExPEC isolates from the United States, ST95 was the
second most common ST, after ST131. These include reports by Adams-Sapper et al. (6),
who examined bloodstream isolates from a San Francisco, CA, hospital; Bannerjee et al.
(7), who examined isolates from blood, urine, and other extraintestinal sites from
Olmsted County, Minnesota; and Salipante et al. (5), who examined urinary and
bloodstream isolates from the University of Washington Hospital system (Seattle, WA).
ST131 clinical isolates typically are multidrug resistant (MDR), expressing ﬂuoroquinolone resistance due to chromosomal mutations and, in many instances, extendedspectrum ␤-lactam resistance due to acquired plasmid-borne or chromosomal genes (8,
9). In contrast, ST95 isolates are much less frequently antibiotic resistant than ST131
strains and many other clonal groups (4). Furthermore, Adams-Sapper et al. (6) noted
that, at least in San Francisco, the ﬁmH6 sublineage of the ST95 group was nearly
always pansusceptible and yet very common. This implies, ﬁrst, that antimicrobial
resistance may not be a major factor contributing to the pandemicity of ST95 strains,
and second, that there may be something distinctive about ﬁmH6 strains with respect
to acquisition or maintenance of antibiotic resistance.
We describe here the use of whole-genome sequence analysis to explore these
implications. We sequenced 44 ST95 bloodstream isolates from San Francisco General
Hospital (SFGH) that had been recovered between 2007 and 2011 (6, 10). These initial
strains encompassed the four major sublineages of ST95, as deﬁned by alleles of the
ﬁmH marker. We added more geographic diversity with four ST95 isolates from
Minnesota (11) and ﬁve from other locations in the United States (12). Finally, we
included archived sequences of 33 ST95 isolates from the Seattle area (5) in our analysis.
Through this approach, we were able to identify the genetic basis for acquired
antibiotic resistance genes in a large United States-based sample of ST95 isolates and
to identify genomic differences between pansusceptible and resistant isolates that help
explain disparities in resistance within the ST95 group.
RESULTS
Genome sequencing and isolate characterization. A total of 53 E. coli ST95
isolates were subjected to whole-genome sequencing on the Illumina MiSeq platform,
followed by de novo assembly and analysis (Table 1; see Table S1 in the supplemental
material). Most (83%) of the isolates were from San Francisco, CA. We also examined
archived whole-genome sequences of 33 ST95 isolates from the Seattle, WA, region (5).
The ﬁmH gene, which encodes an adhesin critical for urinary tract pathogenesis, has
proven to be useful as a genetic marker to increase the resolution of MLST with ExPEC
strains (13, 14). Examination of ﬁmH genotypes from genome sequences allowed
assignment of the ST95 isolates to sublineages (Table 1). Alignment of scaffolded
assemblies from the draft genome sequences and subsequent tree building (Fig. 1)
showed the ﬁmH sublineages to be phylogenetically coherent, with the major division
being between ﬁmH1 and ﬁmH6 isolates, and with the ﬁmH9 and ﬁmH47 clusters
emerging from separate branches of the ﬁmH1 group. Among the isolates we sequenced, the ﬁmH6 genotype was most abundant (48%), followed by the ﬁmH1 (31%),
ﬁmH47 (17%), and ﬁmH9 (3%) genotypes.
Based on their ﬁmH genotype and antibiotic resistance phenotypes, four ST95
isolates from San Francisco were selected for long-read, single-molecule real-time
(SMRT) sequencing (Paciﬁc Biosciences) to develop high-quality, fully assembled reference genomes (15). The complete genomes were from SF-166 (ﬁmH6 [pansusceptible,
as deﬁned in Materials and Methods]), SF-173 (ﬁmH47 [MDR]), SF-468 (ﬁmH1 [MDR]),
and SF-088 (ﬁmH9 [MDR]). Key characteristics of the genome sequences are presented in Table S1. The complete chromosomes of the four strains aligned readily,
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TABLE 1 Characterization of E. coli ST95 isolates and genomes
FimH gene
type
ﬁmH1

No. of plasmid replicons presentc
Isolatea
SF-075
SF-094
SF-149
SF-151
SF-264

SF-495
SF-501
SF-522
SF-523
SF-626
MVAST0234
UPEC-061
UPEC-094
UPEC-106
UPEC-136
UPEC-144
UPEC-185
UPEC-249
UPEC-250
UPEC-276
ﬁmH6

SF-083
SF-095
SF-126
SF-166
SF-231

SF-313
SF-335
SF-356
SF-383
SF-384
SF-403
SF-421
SF-423
SF-425
SF-440
SF-452
SF-491
SF-518
SF-560
SF-567
SF-572
SF-596

MVAST0098
MVAST0176

None
None
Amp (blaTEM-1), Tet (tetA)
None
Amp (blaTEM-1), Str (strA, strB, aadA5),
Tet (tetB), Sul (sul1, sul2), Tmp
(dfrA17)
None
Amp (blaTEM-1)
None
None
None
None
None
None
None
None
None
None
None
None
None
None
Amp (blaTEM-1), Str (strA, strB, aadA5),
Tet (tetA), Sul (sul1, sul2), Tmp
(dfrA17)
None
Amp (blaTEM-1)

IncFI
2 (B, C)
1 (B)
1 (B)
1 (B)

IncFII
1
1
1
1

IncB

IncI

1 (B)
1 (B)
1

1 (B)
1 (B)

2
2
1
1
1
1

1

1
1

(B)
(B)
(B)
(B)

1
1
1
1
1
1
1

(B)
(B)
(B)
(B)
(B)
(B)
(B)

1
1
2
1
1
1
1
1
1
1
1
1
1

1
1
3
1
1

(B)
(B)
(A, B, C)
(B)
(B)

2
1
1
1
1

1
1
1
1
1
1
1
1
1
1
1
1

(B)
(B)
(B)
(B)
(B)
(B)
(B)
(B)
(B)
(B)
(B)
(B)

1
1
1
1
1
1
1
1
1
1
2
1

1
1
1
2

(B)
(B)
(B)
(A, B)

No. of small
plasmidsd
3
6
3
2

Full
pUTI89e

3

1

5
6
4
5
2
7
3

1

1

1
1
1
1

1 (B)
1 (B)

IncQ
1

1

1

1 (B)
1 (B)
1 (B)

IncP

1
1

1
1
1
1

2
2
6
5
6
3
ND
ND
ND
ND
ND
ND
ND
ND
ND

Yes

0
1
0
0
0

Yes
Yes

Yes
Yes
Yes

1
1
1
2

0
2
0
2
0
0
3
0
0
0
0
0
0
0
0
0
2

1
2

0
0

1

1

Yes

Yes
Yes
Yes
Yes
Yes

Yes
Yes
Yes

Yes

(Continued on following page)
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SF-269
SF-305
SF-362
SF-371
SF-380
SF-457
SF-468

Antibiotic resistanceb
Tet (tetA)
Amp (blaTEM-1)
Amp (blaTEM-1)
Amp (blaTEM-1), Str (strA, strB), Tet (tetA),
Sul (sul2), Tmp (dfrA5)
Amp (blaTEM-1), Azm (mphA), Chl
(catA1), Gen (aac3), Nor (gyrA*), Str
(aadA1, aadA2, aadA5), Tet (tetA), Sul
(sul1), Tmp (dfrA12, dfrA17)
Amp (blaTEM-1)
Amp (blaTEM-1)
Amp (blaTEM-1)
Amp (blaTEM-1)
None
Amp (blaTEM-1)
Amp (blaTEM-1), Cef (blaCTX-M14), Gen
(aac3), Str (strA, strB), Tet (tetA), Sul
(sul2), Tmp (dfrA17)
None
Amp (blaTEM-1), Str (strA, strB), Tet
(tetD), Sul (sul2), Tmp (dfrA5)
Amp (blaTEM-1), Str (strA, strB), Tet (tetB)
None
Amp (blaTEM-1)
None
None
blaTEM-1, dfrA5
None
None
blaTEM-1, strA, strB, sul2, dfrA5
blaTEM-1, strA, strB, sul2, dfrAf
None
blaTEM-1, strA, strB, sul2, dfrA5
None

Stephens et al.

TABLE 1 (Continued)
FimH gene
type

Isolatea
USVAST184
USVAST267
Blood-11-0031
UPEC-007
UPEC-008
UPEC-048
UPEC-051
UPEC-072
UPEC-073
UPEC-075
UPEC-098
UPEC-124
UPEC-131
UPEC-139
UPEC-157
UPEC-197
UPEC-255

Antibiotic resistanceb
None
None
None
blaTEM-1, strB
None
blaTEM-1
None
None
None
None
Nonef
Nonef
Nonef
None
Nonef
blaTEM-1
None

SF-088
SF-239
MVAST326

ﬁmH47

SF-001
SF-173
SF-194
USVAST245
USVAST356
USVAST406
Blood-08-0493
Blood ⫺08 to 654
Blood-09-0751
Blood-10-687
UPEC-076
UPEC-120
UPEC-129
UPEC-169
UPEC-209

IncFI
1 (B)
1 (B)

IncFII
1
1
1

3 (A, B, C)
1
1

1 (B)
1 (B)
1 (B)

1
1
1

1 (B)
1 (B)
1 (B)

1
1

1 (B)

1

Amp (blaTEM-1), Str (strA, strB), Sul (sul2),
Tmp (dfrA5)
None
None

1 (B)

1

1 (B)
1 (B)

1
1

Amp (blaTEM-1)
Amp (blaTEM-1), Azm (mphA), Str
(aadA2), Sul (sul1), Tmp (dfrA12)
Amp (blaTEM-1), Chl (catA1), Str (aadA1),
Sul (sul1), Tet (tetA)
None
Amp (blaTEM-1)
Amp (blaTEM-1)
None
None
blaTEM-1, strA, strB, sul2
None
None
None
None
None
blaTEM-1, strA, strB, sul2, dfrA14, tetB

1 (B)

1
1

3 (A, B, C)

1

1
2
3
1
1

1
1
1
1
1

1 (B)

1

1
1
1
1

1
1
1
1

(B)
(B)
(B)
(B)

IncI

IncP

IncQ

1

1

1 (B)
1 (B)

(B)
(A, B)
(A, B, C)
(B)
(B)

IncB
1
1

1

1

Full
pUTI89e
Yes

Yes
Yes
Yes
Yes

Yes

2
0
4

1
1

0
0
1

1

No. of small
plasmidsd
0
2
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND

0
2
0
0
ND
ND
ND
ND
ND
ND
ND
ND
ND

Yes
Yes
Yes

Yes
Yes

aSF

isolates were from San Francisco General Hospital (6), MVAST isolates were from Minneapolis (11), USVAST isolates were from other states in the United States
(10), and “Blood” and “UPEC” isolates were from Seattle (5).
bAntibiotic resistance phenotypes are shown for all strains other than those from Seattle, with the ResFinder-identiﬁed gene(s) (20) presumed responsible shown in
parentheses. For Seattle isolates, only the genes identiﬁed are shown, as phenotypes were not independently conﬁrmed in this study. Antibiotic abbreviations: Amp,
ampicillin; Azm, azithromycin; Cef, cephalothin; Chl, chloramphenicol; Gen, gentamicin; Nor, norﬂoxacin; Str, streptomycin; Tet, tetracycline; Sul, sulfamethoxazole;
Tmp, trimethoprim.
cPlasmid replicons were predicted with PlasmidFinder (25).
dThe number of small plasmids was determined from sequence assemblies, as described in Materials and Methods. Seattle isolates are listed as “ND” (no data), as
these genomes were downloaded as assembled contigs without topology or coverage data, which precluded identiﬁcation of small plasmids.
ePrediction of the presence of pUTI89 is described in Materials and Methods.
fThe presence of resistance genes is discordant with phenotypes reported in reference 5: UPEC-007 (reported as Tetr), UPEC-098 (reported as Ampr Sulr Tmpr), UPEC124 (reported as Ampr Sulr Tmpr), UPEC-131 (reported as Ampr Cefr Tetr), UPEC-144 (not reported as Sulr Tmpr), UPEC-157 (reported as Ampr), UPEC-185 (not reported
as Ampr Sulr Tmpr).

with ⬎99.9% identity across most of the genome (see Fig. S1 in the supplemental
material). Most breaks in the alignment between the complete chromosomes
involved prophages. Other discontinuities in the alignments involved loci for
synthesis of O-antigens and P-pili. O-antigen loci are common sites of recombination and variation in E. coli; the ST95 isolates examined in this work varied in the
O-antigen loci and predicted serotypes, even within ﬁmH types (data not shown).
Additionally, a 40-kb segment located at approximately 0.8 Mb in SF-166 and SF-088
was moved to 4.6 Mb in SF-468 and SF-173. This segment includes the pap genes
encoding P-pili, an important ExPEC virulence factor (16).
March/April 2017 Volume 2 Issue 2 e00390-16
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Because clustered regularly interspaced short palindromic repeat (CRISPR) elements
are thought to impact mobile gene acquisition (including plasmids bearing antibiotic
resistance) in bacterial genomes (17), we examined CRISPR loci in the fully assembled
ST95 genomes. All four isolates lacked the CRISPR1 locus and had only two imperfect
and identical spacers at CRISPR2 (located at ~1.12 Mb), as has been observed previously
in ST95 isolates (18). CRISPR3 and CRISPR4 (located at ~3.2 Mb) were present, with a
variable number of repeats (for CRISPR3, SF-088, 4, SF-166, 7, SF-173, 8, and SF-468, 5;
for CRISPR4, SF-088, 2, SF-166, 6, SF-173, 6, and SF-468, 6). When draft genomes were
examined, there was some variation in repeat numbers within ﬁmH lineages as well
(data not shown).
SMRT sequencing allowed identiﬁcation of DNA methylation patterns (19). All four
genomes displayed adenine methylation (m6A) at GATC sites, attributable to Dam DNA
methyltransferase (see Table S2 in the supplemental material). The SF-468 and SF-173
isolates shared an additional m6A motif, as did the SF-166 and SF-088 isolates. SF-088
showed m6A methylation at two additional sites. All motifs showing m6A methylation
were nearly 100% methylated. The SF-166 genome was the only one to show cytosine
(m4C) methylation, at roughly one out of eight RCCGGY sequences. The SF-166 genome
contains three annotated DNA-cytosine DNA-methyltransferase genes: a homolog of
dcm (located at ~2.1 Mb) that was present in all of the other ST95 genomes sequenced,
a component of a restriction-modiﬁcation system (located at 4.12 Mb) found in all
ﬁmH6 and ﬁmH9 isolates, and a 1.2-kb gene located at 4.16 Mb in SF-166 that was
universal in ﬁmH6 isolates but absent in the non-ﬁmH6 ST95 genomes examined. The
latter gene is hypothesized to be responsible for the unique m4C methylation observed
in SF-166, but this was not conﬁrmed experimentally.
Antibiotic resistance. Thirty-four (40%) of the 86 genomes we examined contained
at least one resistance gene, as identiﬁed by ResFinder (20). Resistance genes were
detected for seven classes of antimicrobial agents (Table 2). For the 53 isolates we
March/April 2017 Volume 2 Issue 2 e00390-16
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FIG 1 Phylogenetic tree showing relationships between ST95 isolates based on alignment of scaffolded genome assemblies. Raw sequencing reads for each
genome were trimmed and ﬁltered for quality control and then assembled to the E. coli SF-166 complete genome sequence (GenBank accession no. CP012633).
The resulting genome sequences were aligned using progressiveMauve 2.4.0 (38), and an unrooted tree based on the alignments was generated using
Archaeopteryx 0.9920. Isolate names are shown to the right, along with ﬁmH type and whether the isolate also contains a pUTI89* plasmid.

Stephens et al.

TABLE 2 Summary of antibiotic resistance gene frequencies in ST95 genomes
Proportion (%) of genes in:
All isolates
Antibiotic class
␤-Lactams
Aminoglycosides
Tetracyclines
Sulfonamides
Trimethoprim
Macrolides
Chloramphenicols

Resistance gene(s)
identiﬁed
blaTEM-1, blaCTX-M14
aadA1, aadA2, aadA5,
aac3, strA, strB
tetA, tetB, tetD
sul1, sul2
dfrA5, dfrA12, dfrA17
mphA
catA1

ﬁmH6 isolates

Non-ﬁmH6 isolates

San
Francisco
21/44 (48)
10/44 (23)

Seattle
9/33 (27)
6/33 (18)

Other
3/9
0

San
Francisco
4/22 (18)
2/22 (9)

Seattle
3/15 (20)
1/15 (7)

Other
1/4
0

San
Francisco
17/22 (77)
8/22 (36)

Seattle
6/18 (33)
5/18 (28)

Other
2/5
0

9/44
9/44
8/44
2/44
2/44

1/33 (3)
5/33 (15)
5/33 (15)
0/33
0/33

0
0
0
0
0

3/22 (14)
2/22 (9)
2/22 (9)
0/22
0/22

0/15
0/15
0/15
0/15
0/15

0
0
0
0
0

6/22
7/22
6/22
2/22
2/22

1/18 (6)
5/18 (28)
5/18 (28)
0/18
0/18

0
0
0
0
0

(20)
(20)
(18)
(5)
(5)

(27)
(32)
(27)
(9)
(9)
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sequenced and assessed for resistance, predictions by ResFinder correlated well with
observed phenotypes. For the Seattle isolates, intact resistance genes were assumed to
confer the expected phenotype. Resistance genes were not evenly distributed among
ﬁmH sublineages: only 8 (20%) of 41 ﬁmH6 isolates contained one or more acquired
resistance genes, versus 1 (33%) of 3 ﬁmH9 isolates, 7 (47%) of 15 ﬁmH47 isolates, and
18 (67%) of 27 ﬁmH1 isolates (for ﬁmH6 versus non-ﬁmH6 isolates, P ⬍ 0.001). With
respect to geographic origin, the Seattle ST95 isolates were signiﬁcantly less likely to
contain genes for ␤-lactam and tetracycline resistance (P ⫽ 0.01 and 0.02, respectively)
than the San Francisco isolates, a result attributable to the non-ﬁmH6 component of the
population.
The aminopenicillin resistance gene blaTEM-1, found in 38% of isolates, was the most
common acquired resistance gene. Most blaTEM-1 genes were located in the context of
Tn3 mobile elements. The only extended-spectrum ␤-lactamase (ESBL) gene identiﬁed,
blaCTX-M-14, was on plasmid pSF-468-2 in strain SF-468, which also contained blaTEM-1 on
a separate plasmid (pSF-468-1). Among the 33 ampicillin-resistant isolates, 15 were
resistant to at least three classes of antibiotics. The MDR isolates accounted for nearly
all detected genes conferring resistance to aminoglycosides, tetracyclines, and sulfamethoxazole/trimethoprim (Table 1). Sulfonamide and trimethoprim resistance genes
were typically coresident (occurring together in 12 of 15 isolates with either type of
gene) and in close proximity on the same contig. One strain (SF-264) was also resistant
to ﬂuoroquinolones due to the presence of typical chromosomal mutations (in gyrA,
Ser83-to-Leu and Asp87-to-Asn; in parC, Ser80-to-Ile) encountered in ﬂuoroquinoloneresistant clinical E. coli isolates (21).
Plasmid content of ST95 genomes. Each of the SMRT-sequenced and fully assembled ST95 genomes contained at least one circular plasmid larger than 90 kb. These
large plasmids all contained one or more known Inc replicons (Table S1), and with one
exception (pSF-166-1), all of the large plasmids contained antibiotic resistance genes.
Furthermore, all of the resistance genes in the three sequenced MDR isolates were
contained on large plasmids. pSF-468-1 carried blaTEM-1 in a Tn3-type transposon
adjacent to a 17-kb region containing genes for resistance to streptomycin (strAB),
sulfonamides (sul2), trimethoprim (dfrA17), and tetracycline (tetA). pSF-088-1 carried
blaTEM-1, sul2, dfrA5, strA, and strB in an 11-kb region, while pSF-173-1 included dfrA12,
aadA2, sul1, and mphA in a 10-kb region. The large IncF plasmids (pSF-468-1, pSF-088-1,
pSF-173-1, and pSF-166-1) shared roughly 40 kb of sequence encoding conserved
replication and conjugation functions. pSF-468-1 also shared with pSF-088-1 another
~45 kb of sequence that included genes encoding potential virulence-associated
factors, such the Sit manganese-iron transport system and genes for aerobactin siderophore production and uptake. Virulence factors in the ST95 genomes will be
reported in greater detail elsewhere.
pSF-166-1, the 114-kb plasmid from pansusceptible strain SF-166, was the only large
plasmid not encoding antibiotic resistance and the only one with a full-length match
(⬎98% identity, 100% coverage) to previously described plasmids: pUTI89 from uroMarch/April 2017 Volume 2 Issue 2 e00390-16
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TABLE 3 Relationship between ﬁmH type, pUTI89*, and antibiotic resistance
Proportion (%) antibiotic resistant
with:
Isolates
Total
ﬁmH6 isolates
Non-ﬁmH6 isolates
aP

No. of isolates
86
41
45

pUTI89* present
2/27 (7)
2/21 (9.5)
0/6 (0)

pUTI89* absent
32/59 (54)
6/20 (30)b
26/39 (67)b

P valuea
⬍0.001
0.13
0.003

values were calculated using the chi-square test.
prevalence of resistance among ﬁmH6 versus non-ﬁmH6 isolates without pUTI89*, P ⫽ 0.01.

bFor
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Downloaded from http://msphere.asm.org/ on April 8, 2017 by guest

pathogenic E. coli strain UTI89 (22), plasmid pRS218 from meningitis-associated E. coli
strain RS218 (23, 24), and plasmid pEC14_114 from uropathogenic strain EC14 (25). This
plasmid carries several candidate virulence factors and has been associated with
virulence in a mouse UTI model (26) and a rat model for neonatal meningitis (24). For
practical purposes, we will refer to this group of plasmids and the close relatives
identiﬁed in this work as pUTI89* unless greater speciﬁcity is needed.
Examination of our draft genomes showed that pUTI89* was common. When pUTI89
was used as the scaffold for reference-guided assemblies of reads from all 53 isolates
we sequenced, a complete version of pUTI89* (deﬁned as ⬎98% of pUTI89 assembled)
was likely present in 16 isolates—14 from San Francisco, one from Sacramento, and one
from Minnesota (Table 1)—all of which were ﬁmH6 strains. Among the Seattle ST95
isolates (see Materials and Methods), 11/33 likely contained pUTI89*, including 1/9
ﬁmH1 isolates, 5/15 ﬁmH6 isolates, and 5/9 ﬁmH47 isolates. Overall, pUTI89* was likely
present in 27 (32%) of 86 ST95 genomes we examined. It was most common in ﬁmH6
isolates (21/41 [51%]), less common in ﬁmH47 isolates (5/15 [33%]), and rare in ﬁmH1
isolates (1/29 [3%]) (for the three-group comparison, by 2 test, P ⫽ 0.0014).
pUTI89*-containing isolates rarely contained acquired antibiotic resistance genes
(2/27 [7%]) compared to the ST95 isolates lacking pUTI89* (27/59 [46%]) (P ⬍ 0.001).
Because most pUTI89*-containing isolates were also in the ﬁmH6 sublineage, and ﬁmH6
isolates were also less likely to be resistant than non-ﬁmH6 isolates, we examined
whether these traits were independently associated with resistance frequency in this
population of isolates (Table 3). Among ﬁmH6 isolates, resistance genes were less
common among isolates with pUTI89* than among those without pUTI89* (2/21 [10%]
versus 6/20 [30%]), but the difference was not signiﬁcant (P ⫽ 0.10). Among non-ﬁmH6
isolates, pUTI89* was also associated with reduced resistance frequency (0/6 resistant
isolates containing pUTI89 versus 26/39 resistant isolates lacking pUTI89; P ⫽ 0.002).
Comparing all isolates lacking pUTI89*, ﬁmH6 isolates were still less likely to be resistant
than non-ﬁmH6 isolates (6/20 [70%] versus 26/39 [33%]; P ⫽ 0.007). These data suggest
that both the ﬁmH genotype (speciﬁcally ﬁmH6) and the presence of pUTI89* may be
associated with reduced carriage of antibiotic resistance genes.
The published sequences of pUTI89 and pRS218 differ by only 16 single nucleotide
polymorphisms (SNPs). Alignment of the assembled sequences from this study showed
that pSF-166-1 differs from pUTI89 by 32 SNPs and from pRS218 by 40 SNPs. Many of
the plasmids from San Francisco isolates were more closely related, including pSF403-1, pSF-420-1, and pSF-440-1 (7 SNPs), which were obtained from separate patients
in late 2009 and early 2010, and pSF-560-1 and pSF-567-1 (6 SNPs), obtained from
separate patients in October 2010. Given the expected rate of false-positive SNPs in
assemblies from MiSeq data (1 ⫻ 10⫺4) (27) at comparable coverage, the plasmids in
these isolates may in fact be identical.
Although large plasmids were assembled readily from SMRT sequencing data, they
rarely assembled as circular contigs from shorter MiSeq reads, so it was not possible to
reliably assess the presence of such plasmids in draft genomes. As an alternative, we
used PlasmidFinder (28) to identify replicons from various incompatibility (Inc) groups
in draft genome sequences. A total of 190 IncF (IA, IB, IC, or II), IncB, IncI, IncP, or IncQ
plasmid replicons were detected in the 86 ST95 genomes examined (mean, 2.2 per
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TABLE 4 Plasmid content in isolates containing or lacking the pUTI89-like plasmid

Genome group
ST95 isolates sequenced
in this work

All ST95 genomes
examined

Isolates with pUTI89*

Isolates with partial or no
pUTI89-like plasmid

Plasmid feature(s) analyzed
Total Inc replicons

No. of isolates
16

Mean (SEM)
2.4 (0.2)

No. of isolates
37

Mean (SEM)
2.5 (0.2)

P value
0.54

Inc replicons, excluding
IncFIB/IncFII
Small plasmids

16

0.2 (0.1)

37

0.7 (0.1)

0.03

16

0.5 (0.2)

37

2.2 (0.4)

0.006

Total Inc replicons

26

2.2 (0.1)

60

2.2 (0.2)

0.99

Inc replicons excluding
IncFIB/IncFII

26

0.1 (0.1)

60

0.6 (0.1)

0.004
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genome; standard error of the mean [SEM], 0.11; range, 0 to 5) (Table 1). PlasmidFinder
failed to identify plasmid replicons in only ﬁve genomes (6%), four of which were ﬁmH6
strains. Most isolates (83%) contained both IncFIB and IncFII replicons (Table 1); only
9/86 lacked an IncFII replicon, and only 12/86 lacked an IncFIB replicon. The mean
number of Inc replicons per strain did not differ signiﬁcantly by ﬁmH lineage. However,
replicon type exhibited a borderline signiﬁcant association with ﬁmH lineage: ﬁmH1
isolates more frequently contained replicons other than FIB and FII (13/27 [48%]) than
did ﬁmH6 (8/41 [20%]) or ﬁmH47 (5/15 [33%]) isolates (P ⫽ 0.051).
Because in the draft genomes most large plasmids did not assemble as single
contigs, whether antibiotic resistance genes were plasmid associated could not always
be determined deﬁnitively. However, 35 (64%) of 55 identiﬁed antibiotic resistance
genes were located on the same contigs as Inc replicons or on pAnkS (see below),
suggesting that most resistance genes were plasmid-borne, similar to the pattern
observed in the fully assembled genomes.
Strains containing pUTI89* had the same mean number of Inc replicons (2.2/strain)
as those lacking pUTI89* (Table 4). However, for pUTI89*-containing isolates, nearly all
Inc replicons were IncFIB or IncFII and were presumably present on pUTI89 itself.
Isolates without a complete pUTI89 were more likely to contain non-IncFIB/FII replicons
or small plasmids (37/59 [63%]) than were pUTI89*-containing isolates (4/27 [15%]) (P ⬍
0.001) (Table 4). Thus, the presence of pUTI89* was associated with a signiﬁcantly lower
prevalence of other plasmids.
Genomes of pansusceptible ST95 isolates were less likely to contain plasmids than
those of resistant strains: the mean number of Inc replicons was lower for isolates
lacking resistance genes (mean, 1.9) than for those containing one or more resistance
genes (mean, 2.7) (P ⬍ 0.001 by Student’s t test). In the genomes we sequenced, the
number of small plasmids was also lower in isolates lacking antibiotic resistance (mean
of 0.9 small plasmids/isolate) (P ⫽ 0.002). Included among the 52 pansusceptible strains
were ﬁve that lacked Inc replicons and small plasmids altogether.
Small plasmids in ST95 genomes. Of the 53 ST95 genomes we sequenced, 26
(49%) contained small plasmids (Table 1), appearing in the draft genome assemblies as
circular contigs of less than 10 kb (see Materials and Methods). PlasmidFinder identiﬁed
some of these as containing replicons of colicin-producing plasmids, but most were not
ﬂagged by PlasmidFinder and lacked the Inc replicons enumerated above. Veriﬁcation
that these contigs represented small plasmids was demonstrated by isolation of
plasmid DNA in the laboratory (see Fig. S2 in the supplemental material). ﬁmH1 isolates
were much more likely to contain at least one small plasmid (17/18 [94%]) than ﬁmH6
isolates (6/26 [23%]) (chi-square test, P ⬍ 0.001). ﬁmH1 isolates also contained more
small plasmids per isolate (3.8/isolate; SEM, 0.4; range, 2 to 7) than ﬁmH6 isolates (mean,
0.5; SEM, 0.2; range, 0 to 3). Isolates containing pUTI89* (many of which are ﬁmH6
strains) also contained signiﬁcantly fewer small plasmids than isolates lacking pUTI89*
(Table 4).
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The vast majority of small plasmids identiﬁed had no antibiotic resistance genes or
known virulence factor genes. An exception was an 8.3-kb plasmid encoding ampicillin
resistance that was present in six ﬁmH1 isolates (SF-94, -149, -305, -457, -522, and -626),
isolated over a 4-year period (2007 to 2011). This plasmid and the accompanying
␤-lactam resistance could be moved into laboratory E. coli strains by transformation,
allowing it to be separated from other small plasmids present in the clinical isolates
(Fig. S2). All ST95 isolates containing the 8.3-kb plasmid showed an elevated cephalothin MIC (32 g/ml versus 12 g/ml for other strains containing blaTEM-1), perhaps due
to an increased blaTEM-1 gene dosage relative to larger, lower-copy-number plasmids in
other ST95 strains.
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DISCUSSION
The work presented here explores genomic diversity and antibiotic resistance in the
E. coli ST95 lineage. Our results suggest that most antibiotic resistance in ST95 strains
is associated with large conjugal plasmids. In the SMRT-sequenced SF-088, SF-173, and
SF-468 strains, all resistance genes were borne on large multireplicon plasmids. This
likely was true also for isolates sequenced to the draft level, since in them most
resistance genes were found on contigs containing IncF replicons, as was the case for
resistance plasmids in the SMRT-sequenced strains. Intriguing exceptions included six
San Francisco isolates containing an 8.3-kb plasmid nearly identical to pAnkS, previously reported in Salmonella enterica isolates in Turkey (29) and Uruguay (30). None of
the non-San Francisco isolates examined contained a pAnkS-like plasmid, but the
temporal and geographic distribution of isolates was far from comprehensive. The
pAnkS-containing strains were all isolated between 2007 and 2011; determination of
whether this plasmid is still contributing to aminopenicillin resistance in San Francisco
or elsewhere warrants further effort.
We also sought to shed light on why ST95 strains are less frequently antibiotic
resistant than many other major ExPEC lineages. In previous work, among ST95 clinical
isolates from San Francisco the ﬁmH6 sublineage was most closely associated with
pansusceptibility (6). The present analysis of an expanded set of isolates conﬁrmed that
ﬁmH6 isolates were signiﬁcantly less likely than other ST95 isolates to contain antibiotic
resistance genes. Although antibiotic resistance in ST95 isolates derived largely from
acquired, plasmid-borne genes, it is conceivable that both chromosomal and plasmid
composition could impact the likelihood of acquiring resistance. Indeed, analysis of
data in Table 3 suggests that both the ﬁmH6 genotype and pUTI89* are associated with
a reduced likelihood of resistance.
Chromosomal elements in ﬁmH6 strains such as CRISPR or restriction-modiﬁcation
systems might restrict entry of new plasmids. The ST95 genomes examined here lacked
CRISPR1 and contained only a rudimentary CRISPR2, as is common in the E. coli B2
group that includes ST95 (18). The CRISPR3 and CRISPR4 loci varied somewhat within
and between the ﬁmH lineages within ST95. No correlation was observed between the
number of spacers or the sequences of spacers in ST95 isolates and their resistance to
antibiotics or the presence of particular plasmids. Thus, there is currently no evidence
to suggest that CRISPR-mediated effects on DNA acquisition could account for the
patterns of antibiotic resistance observed in this work.
Multiple restriction-modiﬁcation systems are found in each of the completely sequenced ST95 isolates according to REBASE (31). The genome of pansusceptible isolate
SF-166 contained two ﬁmH6-speciﬁc chromosomal regions: an ~12-kb segment at
4.11 Mb that includes a homolog of the Eco31 restriction-modiﬁcation system (including separate adenine- and cytosine-speciﬁc DNA methyltransferases) and a 31-kb
segment at 4.15 Mb that includes a DNA-cytosine methyltransferase. The pUTI89*
plasmid in SF-166 is also annotated to encode a putative DNA methyltransferase of
unknown speciﬁcity. Analysis of genome methylation patterns showed no adenine
methylation unique to SF-166, but this was the only isolate exhibiting cytosine methylation, and a chromosomally encoded putative cytosine DNA-methyltransferase
unique to the ﬁmH6 lineage was identiﬁed. Whether cytosine methylation in ﬁmH6
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strains has any role in limiting plasmid entry, and thereby affecting acquisition of
antibiotic resistance, is an open question warranting further study.
Many ST95 isolates, particularly within the ﬁmH6 sublineage, contained a large
multireplicon plasmid nearly identical to pUTI89, designated here generically as
pUTI89*. Our data showed that the presence of pUTI89* was correlated with a lower
likelihood of antibiotic resistance (Table 3) and a reduced content of other plasmids
(Table 4). The preferential association of pUTI89* with the ﬁmH6 sublineage seems likely
to at least partially explain why pansusceptibility is so common in this group (6).
We hypothesize that the pUTI89* plasmid (IncF) inhibits the acquisition or maintenance of other plasmids in the same cell. Incompatibility due to replicon competition
could reduce the pool of resistance-bearing plasmids able to establish themselves in
cells already containing the multireplicon pUTI89*. For example, in the ST95 strains we
examined, blaTEM-1 was usually located on contigs containing IncF replicons, and such
plasmids would be incompatible with a resident pUTI89*. Resistance genes also could
be introduced on plasmids from incompatibility groups other than IncF: e.g., the
blaTEM-1-carrying IncB plasmid in pUTI89*-containing isolate SF-335. However, strains
containing pUTI89* also were also less likely to harbor plasmids from non-IncF incompatibility groups (Table 4). Thus, factors other than replicon competition may be
operative and should be tested experimentally.
Several pUTI89-like plasmids were known previously from the literature. Plasmid
pRS218 is derived from E. coli strain RS218, which was originally isolated from a
neonatal meningitis case in San Francisco in 1974 (32), roughly three decades earlier
and thousands of miles separated from the UPEC strains bearing the closely related
pUTI89 and pEC14_114 plasmids, which were isolated in St. Louis, MO, and St. Paul, MN,
respectively. Both DebRoy et al. (25) and Cusumano et al. (26) have presented PCRbased evidence that pUTI89-like plasmids are common in UTI isolates. pUTI89 and the
closely related pRS218 have also been shown to have roles in pathogenesis. A UTI89
derivative cured of pUTI89 was impaired in a mouse UTI virulence model (26), and an
RS218 derivative cured of pRS218 was impaired in a rat pup model of neonatal
meningitis (23). Genes on pUTI89* that could be involved in pathogenesis include those
encoding a potential cytotoxin (senB) and systems possibly involved in iron uptake (cjr)
(26). More detailed dissection of this plasmid has not yet been done due to difﬁculties
working with it. pUTI89 was found to be highly stable during laboratory culture, and
presumably is “in the wild” as well, due at least in part to a stabilization system related
to the ParM ATPase (33) that prevents plasmid loss (26).
In summary, genomic analysis of ST95 ExPEC strains revealed an extensive plasmidome
accounting for acquired antibiotic resistance and an intriguing phenomenon in which a
large plasmid (pUTI89), perhaps in collaboration with chromosomal genes, may inhibit a
subset of ST95 strains from acquiring other plasmids and associated antibiotic resistance.
A deeper understanding of these pansusceptible strains could potentially be exploited to
devise biological strategies to combat drug-resistant Gram-negative bacterial infections.
MATERIALS AND METHODS
Strains and media. The 44 E. coli ST95 isolates with “SF” designations (Table 1) were drawn from the
collection of Gram-negative bacterial strains isolated from bloodstream infections at San Francisco
General Hospital (SFGH) between 2007 and 2011, as described by Adams-Sapper et al. (10). Isolates
MVAST0098 (urine), MVAST0176 (blood), MVAST0234 (urine), and MVAST0326 (urine) were obtained at
the Minneapolis Veterans Affairs Hospital in Minneapolis, MN, in 2010 and 2011 (11). Isolates designated
“USVAST” were obtained in 2011 in VA hospitals from the following locations as described by Colpan et
al. (12): USVAST184, Ann Arbor, MI; USVAST245, Seattle, WA; USVAST267, Sacramento, CA; USVAST356,
Dallas, TX; and USVAST406, Jackson, MS. All of the USVAST isolates were obtained from urine specimens.
Strains were routinely cultivated on Luria-Bertani agar. Antimicrobial susceptibility testing of the SFGH
isolates (10) was performed by a Microscan WalkAway Gram-negative panel (Dade Behring, Inc., Siemens
USA, Deerﬁeld, IL). Extended-spectrum ␤-lactamase (ESBL) production was conﬁrmed by a double-disc
diffusion assay according to 2011 Clinical and Laboratory Standards Institute guidelines, based on
cefotaxime and ceftazidime in Luria-Bertani agar plates with and without clavulanic acid. “Pansusceptible” was deﬁned herein as susceptibility to ␤-lactams (ampicillin and cephalothin), aminoglycosides
(gentamicin, kanamycin, and streptomycin), chloramphenicol, quinolones (nalidixic acid and norﬂoxacin),
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macrolides (azithromycin), tetracyclines, sulfonamides (sulfamethoxazole), and trimethoprim. “Multidrug
resistant” (MDR) was deﬁned herein as resistance to at least three of these classes.
Genomic DNA sequencing. Genomic DNA was prepared from all strains using the Qiagen blood and
tissue DNeasy kit. Library preparation and sequencing using single-molecule real-time (SMRT) sequencing technology (Paciﬁc Biosciences) have been described elsewhere (15). Analysis of DNA methylation
patterns in the SMRT data (19) was done using analysis tools provided by the manufacturer. Library
preparation for the MiSeq platform followed a standard protocol for Illumina-compatible libraries
(Wafergen Biosystems). Samples were fragmented by a Covaris S220 ultrasonicator to generate an
average insert size of 800 bp. After appropriate fragmentation was veriﬁed by an Agilent Bioanalyzer,
samples were loaded on the Wafergen Apollo 324 NGS Library Prep system. Wafergen PrepX library kits
were used for end repair, A-tail addition, adapter ligation, and size selection using AMPure XP beads.
Sample concentration was quantiﬁed with a Qubit ﬂuorometer. Libraries were PCR ampliﬁed to incorporate index tags and ﬂow cell-binding regions. Final libraries were quantiﬁed by Qubit, Bioanalzyer, and
quantitative PCR (qPCR) and then sequenced via a 300-bp paired-end run on a MiSeq instrument using
V3 chemistry and standard Illumina analysis software.
Bioinformatic analysis. For draft genomes, MiSeq reads were screened and trimmed based on
length and quality using BBDUK within the Geneious software package, version R9 (Biomatters, Ltd.). The
trimming process also removed any residual adapter sequences. Trimmed paired reads (4 ⫻ 105 to 1.2 ⫻
106) were assembled de novo into contigs with the Geneious assembler. The number of reads used in
each assembly was sufﬁcient to give a minimum of 25-fold coverage, averaged across all contigs. (A
maximum of 45-fold coverage was used.) Contigs that were ⬍1 kb in length, with ⬍2-fold read coverage,
or with ⬍80% high-quality base calls were eliminated from subsequent analysis. Annotation of contigs
for the analysis presented here was done by the RAST server (34), but sequences submitted to GenBank
were annotated by the NCBI prokaryotic genome annotation pipeline. Previously assembled genomes of
ST95 ExPEC isolates from the Seattle area (5) were downloaded from NCBI for analysis. Prediction of
acquired antibiotic resistance genes employed ResFinder v.2.1 (20). Identiﬁcation of potential plasmid
replicons was done with PlasmidFinder v.1.3 (28). Identiﬁcation of insertion elements was done with
ISFinder (35), and identiﬁcation of lysogenic prophage used PHAST (36).
To determine whether a pUTI89-like plasmid was present in ST95 isolates from Seattle (5), pUTI89 was
used to query the archived draft genomes using BLAST. Contigs or fragments greater than 500 bp (allowing
for the possibility of misassembly) that were ⬎98% identical to the pUTI89 sequence were aggregated. If
⬎98% of the total 114-kb pUTI89 sequence could be generated by combining nonoverlapping contigs or
fragments from an isolate, we considered that isolate to be positive for the pUTI89 plasmid.
Plasmids less than 10 kb were not well represented in the long-read data, as the template DNA had
been size selected to be greater than 5 kb. These plasmids emerged from de novo assembly of 300-base
MiSeq reads. Contigs were designated “small plasmids,” analogous to the “small cryptic plasmids”
identiﬁed in ESBL-producing E. coli strains by Brolund et al. (37), if (i) they assembled de novo as circular
sequences, (ii) they showed read coverage at least 50% higher than the mean coverage of the top ﬁve
chromosomal contigs in the same assembly, (iii) they were ⬍10 kb in size, and (iv) BLAST searches of
GenBank identiﬁed primarily known plasmids, and the contig used as the query covered 80% or more of
the plasmid sequence in GenBank. (The Geneious de novo assembler can produce a circular contig if the
reads on each end of a linearly assembled contig match and those reads do not intersect with each other
anywhere else in the contig.) The archived genomes of the Seattle isolates could not be used for
identiﬁcation of small plasmids through this approach, as topology and read coverage data were not
available for these assemblies.
Statistical analysis. Comparison of population frequencies (e.g., frequency of pansusceptibility) and
calculated P values used the chi-square test, with a signiﬁcance cutoff of P ⫽ 0.05. Comparison of
population means (e.g., mean number of small plasmids per isolate) used Students t test, with a
signiﬁcance cutoff of P ⫽ 0.05.
Plasmid DNA isolation and transformation. Plasmid DNA was isolated from E. coli cultures using
the ZR Plasmid Miniprep Classic kit (Zymo Research). Plasmid DNA was analyzed on 1% agarose gels.
DNA was transformed in chemically competent OneShot E. coli TOP10 cells (Invitrogen) by the manufacturer’s protocol, and colonies were selected on LB agar plus ampicillin (50 g/ml).
Accession number(s). Complete genome sequences have been deposited in DDBJ/EMBL/GenBank
under the following accession numbers: SF-468 chromosome and plasmids, CP012625 to CP012630;
SF-173 chromosome and plasmid, CP012631 and CP012632; SF-166 chromosome and plasmid, CP012633
and CP012634; and SF-088 chromosome and plasmids, CP012635 to CP012638. The whole-genome
shotgun sequencing projects described here have been deposited in DDBJ/ENA/GenBank under the
accession numbers shown in Table S3.
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